LONDON (AP) — The most advanced vaccine for dengue only offers modest protection but could still help millions of people avoid the devastating effects of the disease known as "breakbone fever," according to a large trial. Results from an early trial of the vaccine in 2012 found the vaccine's efficacy was 33 percent and that it failed to protect against one type of dengue; there are four distinct kinds and the vaccine is meant to fight all of them. Some scientists worry the antibodies from a dengue vaccine might have the same effect and say vaccinated children should be monitored for several years.